The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma
Zhi-Wen Yang, Wei A. He, Yun Zheng, Ru-Hai Zou, Wen-Wu Liu, Yuan-Ping Zhang, Chen-Wei Wang, Yong-Jin Wang, Yi-Chuan Yuan, Binkui Li, Yunfei Yuan · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2018
Abstract
Background: To compare the efficacy and safety of long-versus short-interval of transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) patients.Methods: This retrospective analysis enrolled 574 patients with unresectable HCC who underwent at least two sessions of TACE between January 2007 and December 2014.The patients were divided into a short-interval group (SIG) and a long-interval group (LIG) based on the median TACE interval of the first two sessions.Propensity score matching (PSM) identified 476 patients for a comparison of overall survival (OS) and safety.Results: Before matching, the LIG had a longer OS than the SIG (Median: 12.1 vs.
8.7 months; P = 0.003).After matching, median OS in the SIG and LIG were 9.1 and 14.2 months (P < 0.001).The 1-, 2-, and 3-year survival rates were 37.5%, 17.1%, and 9.9% for SIG and 50.1%, 19.3%, and 11.6% for LIG, respectively.The TACE interval was an independent prognostic factor for OS.The LIG had a longer OS than the SIG in Barcelona Clinic liver cancer (BCLC) stage C patients (Median: 10.2 vs. 5.8 months; P < 0.001), but not in BCLC-A or B. The postoperative adverse rates were similar in matched SIG and LIG patients (29.4% vs.
33.6%,P = 0.324).Conclusions: A long interval between the first two sessions of TACE resulted in a better OS than a short interval in patients with unresectable BCLC C-stage HCC.
Open the resolved locator · 10.7150/jca.24250
Metadata licence: OpenAlex metadata (CC0)